While substantial progress has been made in sharing data from clinical trials, many top-selling medicines still fall short ...

In 2017, the CONSORT-CHM Formulas 2017 extension was introduced to enhance the reporting transparency of randomized ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma ...

We also believe regulations over safety reporting can be burdensome and excessive ... The ICR and The Royal Marsden support moves to ensure greater transparency in clinical trials and would recommend ...

IRVINE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon”) (Nasdaq: ELDN) today reported its third quarter 2024 operating and financial results and reviewed recent ...

Analyst Keay Nakae from Chardan Capital maintained a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price target ... primarily revolving around promising clinical trial ...

Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...

Clinical trials are a significant part of the drug development cycle. However, the process has remained unchanged in recent ...

Inovio Pharmaceuticals ( INO -3.64%) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...

Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy data On track to dose first patient in randomized Phase 2 study of uliledlimab ...